Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF EFFECTS OF THE RESTATEMENT TO AMOUNTS IN THE PREVIOUSLY REPORTED CONSOLIDATED FINANCIAL STATEMENTS (Details)

v3.23.1
SCHEDULE OF EFFECTS OF THE RESTATEMENT TO AMOUNTS IN THE PREVIOUSLY REPORTED CONSOLIDATED FINANCIAL STATEMENTS (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Change in fair value of warrant liabilities $ 2,265 $ (1,253)    
Net loss $ (9,107) $ (22,044)    
Basic and diluted loss per common share $ (0.54) $ (3.80)    
Comprehensive loss $ (9,043) $ (22,047)    
Net cash provided by operating activities (11,744) (13,687)    
Additional paid in capital 723,069 697,426 $ 722,049 $ 696,563
Total stockholders' equity $ 18,740 21,183 $ 26,761 42,368
Previously Reported [Member]        
Change in fair value of warrant liabilities      
Net loss   $ (20,791)    
Basic and diluted loss per common share   $ (3.59)    
Comprehensive loss   $ (20,794)    
Net cash provided by operating activities   (13,687)    
Additional paid in capital   706,433   705,570
Total stockholders' equity   31,443   51,375
Revision of Prior Period, Adjustment [Member]        
Change in fair value of warrant liabilities   (1,253)    
Net loss   $ (1,253)    
Basic and diluted loss per common share   $ (0.21)    
Comprehensive loss   $ (1,253)    
Net cash provided by operating activities      
Additional paid in capital   (9,007)   (9,007)
Total stockholders' equity   $ (10,260)   $ (9,007)